Bi-Mix Injection Recalled Due to Lack of Assurance of Sterility
Pharm D Solutions is recalling Bi-Mix Injection due to a lack of assurance of sterility. The product was distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. A lack of assurance of sterility in an injectable drug presents a significant risk of serious health consequences, such as infection, which aligns with the 'Severe' severity criteria.
Plain-English summary
Pharm D Solutions, LLC is recalling Bi-Mix Injection (Alprostadil 80 mcg/Lidocaine 2 mg/mL), NDC 69699-1317-03. The recall is being conducted because of a lack of assurance of sterility. The affected product quantity is 115 milliliters.
The recall covers lots 04112018:50 (Discard by: 10/7/2018) and 08082018:53 (Discard by: 2/4/2019). The product was distributed nationwide. The FDA has classified this recall as Class II.
Consumers and healthcare providers should stop using the affected product and contact Pharm D Solutions, LLC for further instructions or a refund.
The recalled product
- Product
- Bi-Mix Injection (Alprostadil 80 mcg/Lidocaine 2 mg/mL) Pharm D Solutions, Houston, Texas --- NDC 69699-1317-03
- Manufacturer
- Pharm D Solutions, LLC
- Category
- Drug — Injectable
- Hazard
- Affected units
- 115
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: 04112018:50 Discard by: 10/7/2018
- 08082018:53 Discard by: 2/4/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 79 recalled by Pharm D Solutions, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 79 products in this recall →Related recalls
Same manufacturer · Pharm D Solutions, LLC
See all →- SeverePharm D Solutions Recalls Sermorelin/GHRP-2 &6 Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Sermorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls B-Complex Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereFDA Recalls Ipamorelin Acetate Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Testosterone Cypionate Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
Same hazard · sterility
See all →- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Ultra Lubricating Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SeverePharm D Solutions Recalls Trimix Injectable Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls B-Complex Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereAssurance Infusion Recalls Bi-Mix Injections Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Bi-Mix Forte Injections Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereFDA Recalls Alprostadil Injectable Solution Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-04